Navigation Links
Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
Date:5/11/2009

he development of FDA-defined valvulopathy; the decline of Arena's research and development expenses; the planned reduction of Arena's workforce, including the expected size, timing, related charges and savings, and other expected impact of such reduction; Arena's ability to raise additional funds, including through its agreement with Azimuth; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's ability to obtain additional funds, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs, the charges related to the recent reduction in Arena's workforce may be greater than anticipated, Arena may not realize the savings expected from this reduction, results of clinical trials or preclinical studies may not be predictive of future results, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing and ability of Arena to receive regulatory approval for its drug candidates, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be requ
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
2. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
3. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
6. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
7. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
10. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
11. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)... OncLive® is pleased to ... Thomas Jefferson University has joined its Strategic Alliance ... Partnership program, the Sidney Kimmel Cancer Center at ... of the Center’s cutting-edge research programs, comprehensive approach ... other health care professionals from the Sidney Kimmel ...
(Date:10/19/2014)... CAMBRIDGE, Mass. , Oct. 19, 2014 NextCODE ... of the whole genome in real time, today announced the ... the NextCODE Exchange , at the American Society of ... . To learn more, sign up and apply for ... on its unique features and benefits can be viewed ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems report ... and forecast of revenue. The Orthopedic braces and support systems ... million by 2018, at a developing CAGR of 4.4% from ... Asian Orthopedic braces and support systems market, to get an ... glimpse of the segmentation of orthopedic braces and support systems ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
... 28, 2011 Cell Therapeutics, Inc. (CTI) (Nasdaq and ... the WBBA Life Science Innovation Northwest Conference on Thursday, ... 607 of the Washington State Conference Center, Seattle, Washington. ... 3, 201110:25 AM PST/1:25 PM EST/7:25 PM CETRoom 607, ...
... a professor of chemistry at Penn State University, has developed ... zinc selenide -- a light-yellow compound that can be used ... allows for a more effective and liberal manipulation of light, ... Such technology could be applied to the development of improved ...
... 25, 2011 GeoVax Labs, Inc. (OTC Bulletin Board: ... and tests innovative HIV/AIDS vaccines, today announced its financial results ... GeoVax reported a net loss of $478,784 for ... a net loss of $843,275 for the comparable period in ...
Cached Biology Technology:New kind of optical fiber developed 2New kind of optical fiber developed 3GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 2GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 3GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 4GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 5GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 6
(Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
(Date:10/17/2014)... This news release is available in German . ... need millions of sperms every day in order to reproduce? ... questions are the topic of the latest issue of the ... 16th, 2014). The evolutionary biologist Steven Ramm from Bielefeld University ... nature, it is not unusual for a female to copulate ...
(Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... have discovered a way to target the immune system to ... Researchers also found evidence that the same mechanism may operate ... online edition of Nature . The findings provide ... harness the immune system to fight cancer and other diseases. ...
... In a loud, crowded restaurant, having the ability to focus ... critical. Nerve cells in the brain face similar challenges in ... this process appears to be oxytocin, typically known as the ... bonding. , , In a study appearing online August 4 ...
... other international plans to evaluate obesity prevention efforts, and ... having their intended impact, says a new report from ... the report concluded that more systematic and routine evaluations ... policies are being implemented and which interventions work best. ...
Cached Biology News:Mechanism offers promising new approach for harnessing the immune system to fight cancer 2Mechanism offers promising new approach for harnessing the immune system to fight cancer 3Study reveals potential role of 'love hormone' oxytocin in brain function 2New IOM report lays out plan to determine effectiveness of obesity prevention efforts 2
... MiniPrep series of robotic workstations is designed ... MiniPrep is the ideal automation platform for ... routine laboratory procedures, improving throughput, process consistency ... for MiniPrep software allows you to control ...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
... HDAC4 - ChIP Grade HDAC4 is ... histone deacetylases, which consists of 1084 amino ... similar to the deacetylase domain of yeast ... the nucleus and cytoplasm in a process ...
Biology Products: